Physician profile
Eric A Lewandowski
NPI 1750362216
$10,119.80
in general payments reported to CMS, 2019-2025
61 companies · $2,906 in 2025
The $2,906 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $694 · 2021: $1,002 · 2022: $1,020 · 2023: $1,625 · 2024: $1,998 · 2025: $2,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,529.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,419.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $982.96 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $878.63 | 2019-2025 | |
| Novo Nordisk INC | $781.34 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $615.01 | 2019-2025 | Prolia, Evenity, Repatha |
| Otsuka America Pharmaceutical, INC. | $482.05 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $419.25 | 2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.60 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $304.06 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $301.18 | 2019-2025 | Zerbaxa, Dificid, Capvaxive |
| Axsome Therapeutics, INC. | $279.22 | 2023-2025 | Auvelity |
| Radius Health, INC. | $248.79 | 2021-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $233.37 | 2019-2025 | Farxiga, Airsupra |
| Viiv Healthcare Company | $220.66 | 2024-2025 | Apretude, Cabenuva, Rukobia |
| Amarin Pharma, INC. | $182.35 | 2020-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lewandowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.